Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area.
Avallone G, Margiotta FM, Bombelli A, Gargiulo L, Foti C, Trave I, Rossi M, Magnaterra E, Pigliacelli F, Malagoli P, Giacalone S, Portarapillo A, Patruno C, Schettini N, Bonzano L, Pezzolo E, Chello C, Gori N, Brunasso G, Veronese F, Ortoncelli M, Tolino E, Azzolini A, Bellinato F, Hansel K, Di Brizzi EV, Gurioli C, Esposito M, Giuffrida R, Barei F, Calzari P, Burroni AG, Gola M, Mariano M, Fargnoli MC, Napolitano M, Grieco T, Peris K, Savoia P, Ribero S, Girolomoni G, Stingeni L, Balato A, Costanzo A, Marzano AV, Narcisi A, Ferrucci SM
Dermatology and TherapyIn the feed 22 Jul 2026, published online 22 Jul 2026, issue 2026 Sep, added to PubMed 22 Jul 2026
Topics: Atopic dermatitis & eczemaBiologics
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
PMID 42487103 · DOI 10.1007/s13555-026-01863-2